K
Keith Bowman
Researcher at Sirna Therapeutics
Publications - 17
Citations - 1727
Keith Bowman is an academic researcher from Sirna Therapeutics. The author has contributed to research in topics: Gene silencing & Oligonucleotide. The author has an hindex of 6, co-authored 15 publications receiving 1653 citations. Previous affiliations of Keith Bowman include Novartis.
Papers
More filters
Journal ArticleDOI
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
David Morrissey,Jennifer A. Lockridge,Lucinda Shaw,Karin Blanchard,Kristi Jensen,Wendy Breen,Kimberly Hartsough,Lynn Machemer,Susan Radka,Vasant Jadhav,Narendra K. Vaish,Shawn Zinnen,Chandra Vargeese,Keith Bowman,Chris S. Shaffer,Lloyd Jeffs,Adam Judge,Ian MacLachlan,Barry Polisky +18 more
TL;DR: The advances demonstrated here, including persistence of in vivo activity, use of lower doses and reduced dosing frequency are important steps in making siRNA a clinically viable therapeutic approach.
Journal ArticleDOI
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication
David Morrissey,Karin Blanchard,Lucinda Shaw,Kristi Jensen,Jennifer A. Lockridge,Brent A. Dickinson,James McSwiggen,Chandra Vargeese,Keith Bowman,Chris S. Shaffer,Barry Polisky,Shawn Zinnen +11 more
TL;DR: These experiments establish the strong impact that siRNAs can have on the extent of HBV infection and underscore the importance of stabilization of siRNA against nuclease degradation.
Journal ArticleDOI
Novel liver-specific TORC2 siRNA corrects hyperglycemia in rodent models of type 2 diabetes
Maziyar Saberi,David Bjelica,Simon Schenk,Takeshi Imamura,Gautam Bandyopadhyay,Pingping Li,Vasant Jadhar,Chandra Vargeese,Weimin Wang,Keith Bowman,Ye Zhang,Barry Polisky,Jerrold M. Olefsky +12 more
TL;DR: The importance of TORC2 in modulating HGP in vivo is demonstrated and a novel, liver-specific siRNA approach for the potential treatment of hyperglycemia and type 2 diabetes is highlighted.
Patent
Method of encapsulating a nucleic acid in a lipid nanoparticle host
TL;DR: In this article, a nucleic acid stream and a stream of lipids are intersected at high linear velocities and with total organic solvent concentrations less than 33% to obtain uniformly small particle sizes.
Patent
Deprotection and purification of oligonucleotides and their derivatives
TL;DR: In this article, a method for synthesis, deprotection, and purification of nucleic acid molecules, such as oligonucleotides comprising one or more ribon nucleotides, is presented.